[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570847":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":93,"collaborators":95,"id":98,"slug":10,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":10,"enrollmentInfo":107,"targetDuration":10,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BGF Initiators",null,"New initiators of BGF without prior BGF exposure",[13],"Drug: Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate","Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist",[9],[21],"BGF, Breztri",[23],{"name":24,"affiliation":5,"role":25},"Michael F Pollack, MS","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[33,44,53,61,69,77,85],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Research Site","NOT_YET_RECRUITING","Mississauga","Canada",{"type":39,"coordinates":40},"Point",[41,42],-79.6583,43.5789,{"lat":42,"lon":41},{"facility":34,"status":45,"city":46,"state":10,"zip":10,"country":47,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"RECRUITING","Hamburg","Germany",{"type":39,"coordinates":49},[50,51],9.99302,53.55073,{"lat":51,"lon":50},{"facility":34,"status":45,"city":54,"state":10,"zip":10,"country":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":10},"Athens","Greece",{"type":39,"coordinates":57},[58,59],23.72784,37.98376,{"lat":59,"lon":58},{"facility":34,"status":45,"city":62,"state":10,"zip":10,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"Milan","Italy",{"type":39,"coordinates":65},[66,67],9.18951,45.46427,{"lat":67,"lon":66},{"facility":34,"status":45,"city":70,"state":10,"zip":10,"country":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":10},"Tokyo","Japan",{"type":39,"coordinates":73},[74,75],139.69171,35.6895,{"lat":75,"lon":74},{"facility":34,"status":35,"city":78,"state":10,"zip":10,"country":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Bucharest","Romania",{"type":39,"coordinates":81},[82,83],26.10626,44.43225,{"lat":83,"lon":82},{"facility":34,"status":45,"city":86,"state":10,"zip":10,"country":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"London","United Kingdom",{"type":39,"coordinates":89},[90,91],-0.12574,51.50853,{"lat":91,"lon":90},{"type":94,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[96],{"name":97,"class":6},"IQVIA Pty Ltd","100570847",false,"NCT06712563","Pooled Analysis of Single-arm Studies of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","Pooled Analysis of Multi-country, Open-label Single-arm, Non-interventional, Multi-center, Cohort Studies of Real-world Outcomes in New Users of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","CHOROS","Inclusion Criteria:\n\n* Patients with moderate to severe COPD and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation\n* Enrolled in on-going single-arm studies\n* Provided consent for secondary use of data\n\nExclusion Criteria:\n\n* Did not provide consent for secondary use of data","ALL","18 Years",{"count":108,"type":109},2000,"ESTIMATED","OBSERVATIONAL","The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary\u002Fprimary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania.",[113],"Pulmonary Disease, Chronic Obstructive","2026-06-15",{"date":116,"type":117},"2026-06-16","ACTUAL",{"date":119,"type":117},"2025-04-17",{"date":121,"type":109},"2026-12-14",{"name":5,"class":6},7]